癌症筛查的圣杯：还是仅仅与本杰明家族有关？
The Unholy Grail of cancer screening: or is it just about the Benjamins?
发表日期：2024 Sep 23
作者：
Miyo K Chatanaka, George M Yousef, Eleftherios P Diamandis
来源：
CLINICAL CHEMISTRY AND LABORATORY MEDICINE
摘要：
生物技术公司 Grail 开发了一种非侵入性血液测试（Galleri 测试），据称可以在早期和可能治愈的阶段检测出 50 种癌症。前瞻性研究最初的有希望的结果以及 Grail 预期的财务成功促使测序巨头 Illumina 以 80 亿美元收购 Grail（2021 年）。此次活动之后，Grail 与英国国家卫生系统合作，在为期 3 年的前瞻性试验中进一步阐明了该测试的功能以及护理标准。第一年年底，英国 NHS 宣布，由于临床表现不理想，他们将暂停该试验，直到分析第一年的数据（已经招募了 140,000 名参与者）。相关各方之间的法律和财务问题目前正在不断变化。我们之前对 Galleri 测试的敏感性和特异性表示担忧。在这篇意见书中，我们重新审视了大肆宣传的技术，并就该测试的使用提供了新的建议。© 2024 Walter de Gruyter GmbH，柏林/波士顿。
The biotechnology company Grail developed a non-invasive blood test (Galleri test) which is claimed to detect 50 types of cancer at early and potentially curable stages. The initially promising results from prospective studies, and the anticipated financial success of Grail led the sequencing giant Illumina to purchase Grail for $8 billion (2021). Following this event, Grail collaborated with the UK National Health System to further clarify the test's capability, in a 3-year prospective trial, along with the standard of care. At the end of the first year, UK-NHS announced that they will suspend the trial due to unsatisfactory clinical performance and until they analyze the data for the first year (which already enrolled 140,000 participants). Legal and financial issues between the interested parties are currently in flux. We previously expressed concerns about the sensitivity and specificity of the Galleri test. In this opinion paper, we revisit the hyped technology, and we provide new suggestions on the use of this test.© 2024 Walter de Gruyter GmbH, Berlin/Boston.